XL388 is primarily used in the field of medical research, particularly in cancer studies. It functions as a potent and selective inhibitor of mTORC1 and mTORC2, which are crucial signaling pathways involved in cell growth and proliferation. By targeting these pathways, XL388 has shown potential in inhibiting the growth of various cancer cells, making it a promising candidate for the development of anticancer therapies. Researchers are exploring its efficacy in preclinical models to understand its impact on tumor suppression and its potential use in combination with other therapeutic agents to enhance treatment outcomes. Additionally, its role in modulating cellular metabolism is being investigated, which could provide insights into novel approaches for managing cancer and other diseases linked to mTOR signaling dysregulation.